Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have received an average rating of “Moderate Buy” from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $66.77.

Several research analysts have weighed in on NTLA shares. Citigroup decreased their price target on shares of Intellia Therapeutics from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Friday, May 10th. Canaccord Genuity Group increased their price target on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Wedbush reiterated a “neutral” rating and issued a $29.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research report on Friday, May 10th. Finally, BMO Capital Markets increased their price target on shares of Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th.

Insider Activity at Intellia Therapeutics

In related news, EVP James Basta sold 2,297 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the transaction, the executive vice president now directly owns 81,571 shares of the company’s stock, valued at $2,691,027.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. bought a new stake in shares of Intellia Therapeutics in the 4th quarter worth about $26,000. Signaturefd LLC increased its holdings in shares of Intellia Therapeutics by 89.3% in the 4th quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock worth $49,000 after buying an additional 751 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Intellia Therapeutics by 35.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock worth $93,000 after buying an additional 793 shares during the last quarter. EntryPoint Capital LLC increased its holdings in shares of Intellia Therapeutics by 61.1% in the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after buying an additional 1,563 shares during the last quarter. Finally, Spire Wealth Management increased its holdings in shares of Intellia Therapeutics by 3,789.0% in the 4th quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock worth $119,000 after buying an additional 3,789 shares during the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Down 0.2 %

Shares of Intellia Therapeutics stock opened at $24.84 on Friday. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -4.63 and a beta of 1.85. The company’s 50 day moving average is $24.59 and its 200 day moving average is $27.19. Intellia Therapeutics has a twelve month low of $19.37 and a twelve month high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. The company had revenue of ($1.92) million for the quarter, compared to the consensus estimate of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 45.35%. During the same quarter in the prior year, the firm earned ($1.40) earnings per share. Sell-side analysts expect that Intellia Therapeutics will post -5.12 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.